Stability-indicating HPLC-DAD method for the determination of empagliflozin

Abstract Background A stability-indicating RP-HPLC method was developed and validated for the estimation of empagliflozin drug and its tablet dosage form using a DAD detector. The mobile phase consisted of methanol/acetonitrile/0.1%OPA (75:20:5). The peak was observed at 2.54 min using 222.0 nm abso...

Full description

Bibliographic Details
Main Authors: Shilpi Pathak, Pradeep Mishra
Format: Article
Language:English
Published: SpringerOpen 2021-08-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43094-021-00329-w
_version_ 1818732995489562624
author Shilpi Pathak
Pradeep Mishra
author_facet Shilpi Pathak
Pradeep Mishra
author_sort Shilpi Pathak
collection DOAJ
description Abstract Background A stability-indicating RP-HPLC method was developed and validated for the estimation of empagliflozin drug and its tablet dosage form using a DAD detector. The mobile phase consisted of methanol/acetonitrile/0.1%OPA (75:20:5). The peak was observed at 2.54 min using 222.0 nm absorption maxima. Results Calibration curve plot was found within the range of 10–50 µg/mL. The coefficient of determination (R 2) was found to be 0.9990. Forced degradation studies were performed for the empagliflozin in various conditions, and the results were calculated as %RSD values and were found to be within the limits. Conclusion The method was validated as per ICH guidelines with respect to all validation parameters.
first_indexed 2024-12-17T23:42:26Z
format Article
id doaj.art-79d73ec74f2545a78e34094e1510b0b0
institution Directory Open Access Journal
issn 2314-7253
language English
last_indexed 2024-12-17T23:42:26Z
publishDate 2021-08-01
publisher SpringerOpen
record_format Article
series Future Journal of Pharmaceutical Sciences
spelling doaj.art-79d73ec74f2545a78e34094e1510b0b02022-12-21T21:28:24ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532021-08-01711810.1186/s43094-021-00329-wStability-indicating HPLC-DAD method for the determination of empagliflozinShilpi Pathak0Pradeep Mishra1Institute of Pharmaceutical Research, GLA UniversityInstitute of Pharmaceutical Research, GLA UniversityAbstract Background A stability-indicating RP-HPLC method was developed and validated for the estimation of empagliflozin drug and its tablet dosage form using a DAD detector. The mobile phase consisted of methanol/acetonitrile/0.1%OPA (75:20:5). The peak was observed at 2.54 min using 222.0 nm absorption maxima. Results Calibration curve plot was found within the range of 10–50 µg/mL. The coefficient of determination (R 2) was found to be 0.9990. Forced degradation studies were performed for the empagliflozin in various conditions, and the results were calculated as %RSD values and were found to be within the limits. Conclusion The method was validated as per ICH guidelines with respect to all validation parameters.https://doi.org/10.1186/s43094-021-00329-wEmpagliflozinRP-HPLCStress studyValidationDAD detector
spellingShingle Shilpi Pathak
Pradeep Mishra
Stability-indicating HPLC-DAD method for the determination of empagliflozin
Future Journal of Pharmaceutical Sciences
Empagliflozin
RP-HPLC
Stress study
Validation
DAD detector
title Stability-indicating HPLC-DAD method for the determination of empagliflozin
title_full Stability-indicating HPLC-DAD method for the determination of empagliflozin
title_fullStr Stability-indicating HPLC-DAD method for the determination of empagliflozin
title_full_unstemmed Stability-indicating HPLC-DAD method for the determination of empagliflozin
title_short Stability-indicating HPLC-DAD method for the determination of empagliflozin
title_sort stability indicating hplc dad method for the determination of empagliflozin
topic Empagliflozin
RP-HPLC
Stress study
Validation
DAD detector
url https://doi.org/10.1186/s43094-021-00329-w
work_keys_str_mv AT shilpipathak stabilityindicatinghplcdadmethodforthedeterminationofempagliflozin
AT pradeepmishra stabilityindicatinghplcdadmethodforthedeterminationofempagliflozin